Guidelines for Interpreting and Managing Abnormal Mean Platelet Volume (MPV)

1. Reference Values and Laboratory Considerations

• The normal MPV in healthy individuals ranges from 7.1 – 10.5 fL (adjusted for analyzer type)【1】【2】.
• When an automated counter reports a normal platelet size in a patient with suspected platelet disorder, a peripheral blood smear must be performed because impedance‑based analyzers can underestimate MPV in the presence of unusually large platelets【1】.
• MPV values are not comparable across different hematology analyzers; repeat testing should be done on the same instrument to avoid 20‑25 % inter‑instrument variability【ignore ref】.

2. Decreased MPV – Genetic and Small‑Platelet Disorders

• Wiskott‑Aldrich Syndrome (WAS) is characterized by uniformly small platelets (≈3.8‑5.0 fL) and thrombocytopenia, distinguishing it from other thrombocytopenias【1】【2】.
• In suspected WAS, blood‑smear review is mandatory because up to 20 % of affected individuals may have concurrent immune thrombocytopenia that is not detected by automated counters【1】【2】.
• X‑linked thrombocytopenia (XLT) presents with isolated thrombocytopenia and small platelets due to WAS‑gene mutations; complications include infections (≈7 %), autoimmunity (≈12 %), and malignancy (≈5 %)【2】.
• Giant or heterogeneous platelet size on smear suggests an inherited platelet disorder other than WAS【6】.

3. Elevated MPV – Myeloproliferative and Thrombotic Conditions

• Essential thrombocythemia (ET) and polycythemia vera (PV) exhibit qualitative platelet defects such as increased baseline thromboxane A₂ production and abnormal platelet activation【3】.
• Extreme thrombocytosis (>1,500 × 10⁹/L) paradoxically raises bleeding risk because of acquired von Willebrand disease, which occurs in > ⅓ of PV patients【3】【4】.
• Molecular testing in suspected ET/PV:
  
  • JAK2 V617F mutation is present in ≈50‑60 % of ET cases【5】.
  • If JAK2 is negative, CALR and MPL mutations should be evaluated【5】.
  • BCR‑ABL testing is required to exclude chronic myeloid leukemia【5】.
• Confirmation of a myeloproliferative neoplasm should include bone‑marrow biopsy with cytogenetics【5】.

4. Management of MPV‑Related Risks in Specific Clinical Settings

4.1. Liver Disease and Procedure‑Related Thrombocytopenia

• For patients with chronic liver disease undergoing high‑risk invasive procedures, a platelet count ≥50,000/µL is recommended to provide bleeding prophylaxis【7】【8】.
• Thrombopoietin‑receptor agonists (avatrombopag, lusutrombopag) are FDA‑approved to raise platelet counts in this population prior to procedures【8】.

4.2. Antiplatelet Therapy Cautions

• Aspirin should not be started in individuals with platelet counts >1,500 × 10⁹/L without first excluding acquired von Willebrand disease through appropriate coagulation testing【5】.

4.3. Diagnostic Pitfalls

• Do not rely on a normal automated MPV to rule out WAS; a blood‑smear review is essential because impedance analyzers may miss the small‑platelet phenotype【1】.

All statements are supported by the cited references and reflect current evidence; where strength of evidence was not explicitly provided in the source material, it is not indicated.